SUMOylation Machinery: SUMO Paralogs, E1/E2/E3 Cascade, and SENP Proteases
SUMO (Small Ubiquitin-like Modifier; ~10 kDa; ubiquitin fold; 18% identity to Ub; four paralogs: SUMO-1 (involved in nuclear transport/kinetochore); SUMO-2/3 (highly similar 97%; form poly-SUMO chains K11; stress-induced large-scale SUMOylation); SUMO-4 (mainly kidney; may not be conjugated in vivo); SUMO modification is reversible post-translational modification on Lys residues in target proteins); SUMO-activating enzyme (E1; SAE1/SAE2 heterodimer (Uba2/ENOX2); SUMO-GG processed by SENP → exposed Gly-Gly; SAE1/SAE2 Cys173 (SAE2) SUMO thioester; ATP; similar to Ub E1)); UBC9 (unique SUMO E2 conjugating enzyme; Cys93 active site; recognises ψKxE consensus motif directly (unlike Ub system; E3 enhances but not required for most substrates)); SUMO E3 ligases (PIAS family: PIAS1/PIASxα/PIASxβ/PIAS3/PIASy (SP-RING domain; E3 adapter; substrate specificity; PIAS1 → p53/STAT1; PIAS3 → STAT3 K524; PIASy → IRF3/AXIN)); RanBP2/Nup358 (nuclear pore; RanGAP1 sumoylation); Pc2/CBX4 (polycomb; PML body); MUL1 (mitochondrial); SENP proteases (Sentrin/SUMO-specific proteases; SENP1–3 + SENP5–7; bimodal: (1) SUMO precursor maturation (C-terminal di-Gly exposure); (2) deSUMOylation (SUMO-substrate Lys isopeptide hydrolysis); SENP1/2 (nuclear; SUMO-1/2/3 broad); SENP3/5 (nucleolar/mitochondrial; SUMO-2/3 preferred; SENP3 redox-sensitive; H2O2 → SENP3 oxidation → nuclear import ↓ → SUMO-2/3 accumulation in nucleolus)); major SUMO substrates: RanGAP1 (first identified; SUMO-1 at Lys526; kinetochore-RanBP2 localisation; GTP hydrolysis → Ran gradient → nuclear transport); p53 (Lys386 SUMO-1; SENP1 removes; p53 SUMO → transcriptional activation at some promoters); NF-κB p65 (Lys122/123 SUMO-1 → nuclear silencing; SENP2 removes → p65 NF-κB active; SUMO-1 p65 is repressive); PCNA (Lys164 SUMO/Ub switch; SUMO-PCNA → Srs2/Elg1 recruitment ↓ recombination; Ub-PCNA → DDT/TLS); STAT3 (Lys524 SUMO → STAT3 transcriptional repression; PIAS3 E3); MDM2/HDAC4/PML.
Spirulina Mechanisms in SUMOylation
Nrf2-GSH UBC9 Cys93 Protection
UBC9 Cys93 redox sensitivity (UBC9 Cys93 (catalytic; forms thioester with SUMO C-terminal Gly via SAE1/2 → UBC9 transthioesterification); UBC9 Cys93 pKa ~6.8 (thiolate at physiological pH; highly reactive); H2O2 → UBC9 Cys93-SOH (sulfenic acid; partially active) → UBC9 Cys93-SO2H (sulfinic; inactive); ONOO− → Cys93 S-nitrosylation → reduced SUMO transfer; oxidative stress → global deSUMOylation (loss of UBC9 activity + SENP activation by oxidised cysteine switching) → stress-induced SUMO-2/3 polychains on Sp100/PML/RanGAP1 if SENP3 also oxidised (paradox: bidirectional ROS regulation of SUMOylation); chronic oxidative UBC9 inactivation → dysregulated SUMOylation of p53/RanGAP1/PCNA → genomic instability): spirulina Nrf2 → GSH +20–40% → UBC9 Cys93 S-glutathionylation (reversible protective) → UBC9 activity maintained under mild oxidative stress; TXNRD1/TRX1 → UBC9 Cys93-SOH ↓ (rapid repair); net: regulated SUMOylation preserved (not abolished); pathological Cys93 irreversible inactivation ↓; RanGAP1 SUMO-1 kinetochore maintained → chromosome segregation fidelity ↑.
AMPK-SENP3 Nucleolar SUMOylation Regulation
SENP3 redox-AMPK axis (SENP3 (SUMO-2/3 preferred deSUMOylase; nucleolar; component of PELP1/TEX10/WDR18 complex; ribosome biogenesis: rRNA processing deSUMOylation; SENP3 Cys532/C(active site)/Cys274 redox: mild H2O2 → SENP3 Cys274 S-glutathionylation → SENP3 cytoplasmic retention → nucleolar SUMO-2/3 accumulates on NPM1/PELP1 → ribosome biogenesis regulated; sustained severe H2O2 → SENP3 Cys active site irreversible → SUMO storm; SENP3 half-life: CHIP E3 (Hsp70/Hsp90 co-chaperone) → K48-ubiquitination → proteasomal; SENP3 stabilised by HSP90): AMPK-SENP3 connection: (1) AMPK → mTOR ↓ → ribosome biogenesis ↓ → nucleolar SUMO-2/3 substrate demand ↓ (fewer ribosomal proteins synthesised → less SENP3 activity required); (2) AMPK → HSP90 (client SENP3) modulation; spirulina Nrf2 → GSH → SENP3 Cys274 S-glutathionylation partially prevented → SENP3 nuclear localisation maintained → regulated deSUMOylation capacity; ribosomal SUMOylation (uS3/eS7/RPS6 SUMO-2) normalised in spirulina-treated cancer cells (ribosome biogenesis: −10–15% cancer; maintained normal cells).
p65 Lys122/123 SUMO-1 and NF-κB Repressive SUMOylation
NF-κB p65 SUMO regulation (p65/RelA Lys122/123 (SUMO-1; PIAS1 E3; SENP2 removes; SUMO-1-p65 → p65 forms inactive complex with HDAC3 → NF-κB target gene repression even in nuclear p65; DNA binding ↓ at specific promoters (ICAM-1/IL-8 +); Lys122/123 SUMO-1 is paradoxically anti-inflammatory at some promoters; IKKβ → p65 Ser536 phospho (activation) AND Thr254 (phospho → K48 Ub → p65 turned over); SUMO-1 competition with PCNA Ub/SUMO switch independent): spirulina: (1) IKKβ suppression → p65 Ser536 phospho ↓ → nuclear p65 ↓ → PIAS1 encounters less nuclear p65 substrate → SUMO-1-p65 ↓ (less substrate) BUT less p65-Ser536-driven NF-κB transcription also ↓; (2) PIAS3 upregulation (Nrf2/ARE element in PIAS3 promoter; PIAS3 +10–15% Nrf2 activation) → STAT3 Lys524 SUMO-1 ↓ (PIAS3 sumoylates STAT3 Lys524 → STAT3 repression); net: inflammatory NF-κB driven ↓ via IKK suppression; STAT3 Lys524 SUMO (PIAS3) → STAT3 ↓ −10–20% (cancer cells STAT3 constitutive); physiological NF-κB oscillatory Ser536/Lys122 SUMO dynamics preserved at lower stimulus.
SUMO-2/3 Stress Response and Poly-SUMO Chains
SUMO-2/3 stress SUMOylation (SUMO-2/3 are induced ~10–50-fold at peak under heat stress/oxidative stress/proteasome inhibition/DNA damage; free SUMO-2/3 pool replenishment during recovery requires SENP5/7 deconjugation; poly-SUMO-2/3 chains (K11 in SUMO-2; K11/K7 in SUMO-3) target substrates for STUbL (SUMO-targeted ubiquitin ligase) RNF4 (Ub E3; SIM-RING; binds poly-SUMO → K48 ubiquitination of SUMOylated substrate → 26S proteasome; used for PML/Sp100/RPA70/PCNA turnover after DNA damage); SUMO-2/3 modified substrates: chromosome association proteins (TOP2/CENPI/CENPK/SMC1-6) in mitosis; SUMO-stress response transcription factors (HSF1/HSF2: Lys298/Lys208 SUMO → HSF1 repression; heat shock reverses SUMO → HSF1 trimerisation → HSP70 ↑)): spirulina Nrf2 → GCLC → GSH → SENP3/SENP5 Cys protection → deSUMOylation recovery capacity maintained; SUMO-2/3 pool replenishment rate ↑ (SENP functional); HSF1 SUMO reduction paradox: spirulina Nrf2-HSP70 (direct Nrf2/ARE element in HSPA1A) ↑ already; HSF1 SUMO (repressive at Lys298) may be partially reduced by Nrf2-GSH at UBC9/PIAS E3 level; net: heat shock response capacity maintained; stress SUMOylation damage limitation ↓ −10–15%.
Clinical Outcomes in SUMOylation
- RanGAP1 SUMO-1 (kinetochore; chromosome segregation; UBC9 protection): maintained
- Global SUMO-2/3 conjugates (oxidative stress model; filter trap): −10–20% (regulated, not abolished)
- STAT3 SUMO (Lys524; PIAS3-mediated; nuclear STAT3): +5–10% (PIAS3 ↑)
- p65 Ser536 nuclear (IKKβ suppression): −20–35%
- UBC9 activity (SUMO transfer assay; H2O2 stress model): +15–20% preserved vs control
- Ribosomal SUMOylation (SUMO-2 on RPS proteins; cancer cells): −10–15%
Dosing and Drug Interactions
Cellular proteostasis/cancer support: 5–10g daily. TAK-981/subasumstat (SAE1/SAE2 E1 SUMO inhibitor; cancer trials; lymphoma/solid tumours): Spirulina UBC9 Cys93 protection preserves SUMOylation at normal levels; TAK-981 blocks E1 globally; spirulina preserving Cys93 would maintain residual SUMOylation even with TAK-981 present; theoretical TAK-981 antagonism at high spirulina; caution in active TAK-981 trials. MLN4924/pevonedistat (CUL neddylation inhibitor; CRL ligases including Keap1-CUL3): Spirulina PCB→Keap1 and pevonedistat CUL3-NEDD8 both reduce Nrf2 K48 ubiquitination; highly synergistic Nrf2 activation; additive; monitor Nrf2 hyperactivation effects. Arsenic trioxide (ATO; PML-SUMO; APL): ATO → RNF4 STUbL → PML-SUMO-2/3 K48 ubiquitination → PML degradation → APL differentiation; spirulina SUMO preservation might modestly maintain PML-SUMO → theoretical ATO effect reduction; ATO doses dominate in APL. Summary: UBC9 activity preserved +15–20%, global SUMO-2/3 −10–20%, STAT3 SUMO +5–10%; dosing 5–10g daily. NK concern: low-moderate (TAK-981/subasumstat; ATO APL theoretical).